Paysign(US:PAYS)2025-11-12 22:09Financial Performance - Third quarter 2025 total revenues reached $21.6 million, reflecting a 41.6% year-over-year growth[4] - Adjusted EBITDA for Q3 2025 was $5.04 million, up 78.1% from the previous year, representing 23.3% of revenues[4] - Net income improved by 54.2% to $2.22 million, with diluted earnings per share increasing to $0.04[4] - Total revenues for Q3 2025 reached $21,596,478, a 41.6% increase from $15,256,431 in Q3 2024[21] - Net income for Q3 2025 was $2,215,135, compared to $1,436,837 in Q3 2024, reflecting a 54.1% year-over-year increase[21] - Adjusted EBITDA for the nine months ended September 30, 2025, was $14,512,453, up from $6,756,410 in 2024, indicating a growth of 115%[26] - The Adjusted EBITDA margin for the three months ended September 30, 2025, was 23.3%, compared to 18.5% in 2024, reflecting an increase of 4.8 percentage points[28] - The EBITDA margin for the nine months ended September 30, 2025, was 19.6%, up from 11.3% in 2024, showing an improvement of 8.3 percentage points[28] - Basic Adjusted EBITDA per share for the nine months ended September 30, 2025, was $0.27, compared to $0.13 in 2024, representing a 108% increase[26] - The net income margin for the three months ended September 30, 2025, was 10.3%, compared to 9.4% in 2024, reflecting an increase of 0.9 percentage points[28] Revenue Breakdown - Pharma patient affordability revenue surged 141.9% to $7.92 million, with 105 active programs, an increase of 39 programs year-over-year[4] - Plasma revenue increased 12.4% to $12.86 million, with 595 plasma centers, up 117 centers from the previous year[4] - Plasma industry revenue was $12,860,478, up from $11,439,534 in the same quarter last year, while pharma industry revenue surged to $7,920,604 from $3,274,888[21] Cash and Assets - The company ended the quarter with $7.53 million in unrestricted cash and zero bank debt[4] - Total assets as of September 30, 2025, were $209,509,085, up from $179,028,197 at the end of 2024[22] - Cash and cash equivalents decreased to $7,529,047 from $10,766,982 at the end of 2024[22] Future Outlook - Full-year 2025 total revenues are now estimated to be between $80.5 million and $81.5 million, reflecting a year-over-year growth of 38.7% at the midpoint[12] - Adjusted EBITDA for the full year is expected to be in the range of $19.0 million to $20.0 million, equating to an Adjusted EBITDA margin of 24.1%[12] - The company plans to add another 20-30 pharma patient affordability programs before year-end, indicating strong demand for its solutions[3] - The company expects to add 20-30 new programs by year-end, indicating strong demand for its solutions[14] - The company anticipates fourth quarter results to be similar to Q3, with flat plasma revenue and additional patient affordability programs[14] - The company is well-positioned to capitalize on growth opportunities in patient affordability and SaaS engagement technology solutions[14] Operational Improvements - The opening of a new customer service contact center has increased support capacity fourfold, preparing the company for significant growth in patient affordability[14] Other Financial Metrics - Stock-based compensation as a percentage of revenue for the three months ended September 30, 2025, was 5.9%, up from 3.8% in 2024, indicating a rise of 2.1 percentage points[28] - Interest income, net, for the nine months ended September 30, 2025, was $(2,031,024), compared to $(2,345,416) in 2024, showing a decrease of 13.4%[26] - Depreciation and amortization for the three months ended September 30, 2025, was $2,190,420, compared to $1,565,621 in 2024, representing an increase of 40%[26]